glp-1 discontinuation weight regain The Gap Between Prescriptions and Persistence Real-world studies of GLP-1 discontinuation

The efficacy and safety of tirzepatide, with a special focus on cardiovascular safety, were investigated in the 52-week SURPASS-4 trial testing tirzepatide versus insulin glargine in adults with T2D and a high cardiovascular risk under inadequate glycemic control at baseline on one to three oral glucose-lowering medications (metformin, sulfonylurea, SGLT-2 inhibitor) (54, 74)

Absence of evidence is not proof of failure

Sample m/z range was set to 3004000 Da

At our medical dermatology clinic on Harley Street, we address this explicitly during consultation

This innovative medication offers a unique approach that addresses the dual challenges of diabetes and weight simultaneously

mSystems 2 (6), e0013017